Tales From The Road
This panel brings together biotech and medtech entrepreneurs to tell their stories of raising capital. You’ll hear their firsthand accounts of navigating the fundraising process and raising capital. Topics may include:
• What stumbling blocks had they hit?
• How had they solved the issues, and what had they learned about raising capital?
• How did they go about finding potential investors, and how did they determine which investors they should pursue?
The panel discusses what the early stage fundraising process was like for them and how others can build an outbound marketing campaign to raise money.
Greg Mannix, VP of International BD, Life Science Nation (Moderator)
Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master’s degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in the medical devices field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg’s role at LSN is to provide international early-stage companies with the tools and strategies to succesfully fundraise and to facilitate cross-boarder investments, licensing and M&A transactions.
Alejandro Zamorano, VP Business Development, PainQx
Handles all strategic and partnering opportunities for PainQx. Alejandro has 10 years of experience in business development finance, marketing, and fundraising in the life sciences. PainQx is an A.I. powered medical device company that has developed a method to objectively measure chronic pain. The PainQx platform achieves this by assessing neural activity using EEG from a patient’s brain and processing and decoding the data through proprietary algorithms. The output is a scaled pain biomarker correlates to a patient’s pain state. The PainQx platform will be used by physicians as a biomarker to gauge the dosage of medication and the efficacy of a treatment regimen. This is an especially pressing need given the opioid epidemic which in 2017 claimed 49,068 Americans. Previously Alejandro was Co-Founder & VP of Business Development at Life Science Nation (LSN), an online platform that helps entrepreneurs connect with investors that fit their investment needs. During Alejandro’s tenure at LSN, the business grew from 1 to 22 employees, opened of a broker-dealer (Boston Innovation Capital), created a quarterly conference (Redefining Early Stage Investments), and the launched the LSN Company and Investor Platform. Previous to LSN Alejandro was Business Development Executive at Abpro a CRO specializing in the development of recombinant proteins, monoclonal antibodies, and the associated assay development. Alejandro joined Abpro as a financial analyst responsible for securing funding. He was then promoted to a role in Business Development. In this role, Alejandro formed discovery and development-stage collaborations with the industry’s largest pharmaceutical companies such as Novartis, Astellas, Boehringer Ingelheim, and Abbott (Now Abbvie).
Hank Wu, CDO, Luminopia
Hank Wu serves as serial entrepreneur and advisory board member in the Boston, Taipei and Jerusalem digital health communities. His startup highlights include advanced analyticsfor electronic health records, Flagship / Google-backed biotech, digital therapeutics for neuro-visual disorders and multi-sided healthcare platforms. Previously, Hank led digital strategy and innovation at Biogen, where he worked on digital biomarkers using computer vision, machine learning and wearables; created the talent development program for digital health; and put the company on the map as thought leader at Bio-IT World and AWS:reInvent. Hank received his left brain from the University of California, Berkeley (electrical engineering and computer science), his right brain from Johns Hopkins University (biotech) and his hindbrain from MIT Sloan. He is a co-author of peer-reviewed scientific publications and patents through his early work at the University of California, Berkeley, the J. Craig Venter Institute and the National Lab for Cancer Research.
Ilana Odess, CEO, Woven Orthopedic Technologies
Ms. Odess has spent her entire career within the healthcare & science industries and has held senior executive roles for multinational companies and start-ups such as Israel Chemicals, Johnson & Johnson, Advanced Stent Technologies, CID. As an operator, Ms. Odess is an expert in leading companies from concept to clinical application and has created multiple businesses acquired by multi-billion dollar medical device companies, negotiated over 30 worldwide partnerships, and commenced direct corporate operations in Israel for Johnson & Johnson. As an investor, Ms. Odess has led international medical technology investments and management buyouts for an international family office and led Johnson & Johnson’s acquisition of two businesses. Ms. Odess has been recognized for her ability to create successful innovative solutions and has received both a Frost & Sullivan award for innovation and the state of Connecticut’s “2014 Woman of the Year” award for Entrepreneurial Innovation and Leadership. Ms. Odess graduated with a BS in Biochemistry and an MBA from Bar-Ilan University.
Kasper Roet, CEO, QurAlis
Kasper Roet is CEO and co-founder of QurAlis Corporation, is an experienced entrepeneur and worked both in industry and academia. Kasper has relevant expertise in ALS and other neuro indications. He received his PhD at the Netherlands Institute for Neuroscience working on gene therapies for paralysis. He co-founded Netfase, was BD and alliance manager at the Harvard Stem Cell Institute and fellow at the Boston Children’s Hospital. He worked at Janssen Vaccines as adjunct technical integrator and assay development lead.